BTK Inhibitors in Relapsed/Refractory CLL

Downloadable slides with expert analysis of the optimal use of BTK inhibitors in patients with relapsed/refractory CLL.
Nicole Lamanna, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 1.04 MB
Released: June 10, 2020

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
AstraZeneca

Related Content

On-demand Clinical Care Options (CCO) webcast with experts’ review of data informing optimal management of relapsed/refractory myeloma

Shaji K. Kumar, MD
Program Director
Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP
Physicians: maximum of 0.75 AMA PRA Category 1 Credits Released: March 31, 2021 Expired: March 30, 2022

From Clinical Care Options (CCO), read an expert commentary on how to safely provide CAR T-cell therapy during the COVID-19 pandemic

person default Caron A. Jacobson, MD Released: March 31, 2021

Free video from Clinical Care Options (CCO) featuring expert discussion of the latest updates in CAR T-cell therapy for hematologic cancers

Renier J. Brentjens, MD, PhD
Program Director
Frederick L. Locke, MD Noopur Raje, MD
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: March 29, 2021 Expired: March 28, 2022

From Clinical Care Options (CCO), a commentary from 3 myeloma experts on selecting treatment for relapsed/refractory disease

Shaji K. Kumar, MD
Program Director
Suzanne Lentzsch, MD, PhD Saad Z. Usmani, MD, MBA, FACP
Released: March 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue